ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
68 023,63
0,44%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC
  6. Anthera Pharmaceuticals Inc (CE) (ANTH)

  7. Anthera Pharmaceuticals Inc (CE) (ANTH) Actualités

ANTH

Anthera Pharmaceuticals (CE) (ANTH)

Anthera Pharmaceuticals Inc (CE)
De:
Trier par:
 Showing the most relevant articles for your search:USOTC:ANTH
DateHeureSourceTitreSymboleSociété
12/09/201821h21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
30/07/201822h45Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
27/07/201812h02Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
20/07/201822h28Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
20/07/201822h28Edgar (US Regulatory)Withdrawal of Registration Statement (rw)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
20/07/201822h28Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
17/07/201820h38Edgar (US Regulatory)(25)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
09/07/201823h08Edgar (US Regulatory)Current Report Filing (8-k)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
27/06/201814h00GlobeNewswire Inc.Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
15/05/201822h00Edgar (US Regulatory)Quarterly Report (10-q)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
12/03/201813h00GlobeNewswire Inc.Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of SollpuraUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
07/03/201814h30GlobeNewswire Inc.Anthera Pharmaceuticals to Present at the 30TH Annual ROTH ConferenceUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
06/03/201823h31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
06/03/201820h45GlobeNewswire Inc.Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing CriteriaUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
05/03/201823h32Edgar (US Regulatory)Annual Report (10-k)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
05/03/201822h05GlobeNewswire Inc.Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial ResultsUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
22/02/201822h29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
08/02/201814h30GlobeNewswire Inc.Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orp...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
05/02/201814h30GlobeNewswire Inc.Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of SollpuraUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
25/01/201822h30GlobeNewswire Inc.Anthera Receives Positive Nasdaq Listing DeterminationUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
22/01/201814h30GlobeNewswire Inc.Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Stud...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
18/01/201823h29Edgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
11/01/201821h07Edgar (US Regulatory)Amended Small Company Offering and Sale of Securities Without Registration (d/a)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
09/01/201823h15GlobeNewswire Inc.Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement OfferingUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
09/01/201812h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
08/01/201814h30GlobeNewswire Inc.Anthera Pharmaceuticals Announces Results of Special Meeting of StockholdersUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
03/01/201814h30GlobeNewswire Inc.Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, ManufacturingUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
11/12/201714h30GlobeNewswire Inc.Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollp...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
04/12/201712h17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
29/11/201722h07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
 Showing the most relevant articles for your search:USOTC:ANTH

Dernières Valeurs Consultées

TSX
JAPN
CI Japan Equity Index ETF
USOTC
SKUEF
Sekisui House Reit (PK)
BIT
F36277
Vontobel Financial Produ...
NYSE
DHT
DHT
BIT
NEXI
Nexi S.p.A
BIT
F31664
Vontobel Financial Produ...
BIT
F06716
Vontobel Financial Produ...
BIT
P1BVZ2
BNP Paribas Issuance
BIT
P118R9
Bnp Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés